3 March 2026
Johnson & Johnson's Nipocalimab Gets FDA Fast Track for Lupus Treatment
Nipocalimab, an investigational therapy, aims to address unmet needs in lupus by reducing harmful IgG while preserving immune function, following positive Phase 2b results.